None of the trials examined the effects of the interventions in terms of costs .
AUTHORS ' CONCLUSIONS The included trials did not demonstrate significant differences for most of the outcomes when targeting intensive perioperative glycaemic control compared with conventional glycaemic control in patients with diabetes mellitus .
However , posthoc analysis indicated that intensive glycaemic control was associated with an increased number of patients experiencing hypoglycaemic episodes .
BACKGROUND Patients with diabetes mellitus are at increased risk of postoperative complications .
Data from r and omised clinical trials and meta-analyses point to a potential benefit of intensive glycaemic control , targeting near-normal blood glucose , in patients with hyperglycaemia ( with and without diabetes mellitus ) being su bmi tted to surgical procedures .
However , there is limited evidence concerning this question in patients with diabetes mellitus undergoing surgery .
OBJECTIVES To assess the effects of perioperative glycaemic control for diabetic patients undergoing surgery .
Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting.
BACKGROUND In diabetic patients , the combination of abciximab with stenting has been demonstrated to be the st and ard of care to reduce target vessel revascularization ( TVR ) and mortality . Moreover , a preprocedural hyperglycemia has been associated with a higher rate of TVR after an elective stent implantation . We sought to evaluate the effects of abciximab and /or preprocedural glycemic control on 30 and 180 days of TVR and on 1-year major adverse cardiac events ( MACE-cardiac mortality , TVR , and myocardial infa rct ion ) in diabetic patients undergoing elective coronary stenting .  METHODS From January 2002 through May 2003 , diabetic patients undergoing elective stenting of de novo coronary artery lesions were r and omized to abciximab or placebo infusion . Preprocedural hyperglycemia was defined as fasting plasma glucose > or=126 mg/dL ( 7.0 mmol/L ) immediately before the procedure . RESULTS A total of 122 consecutive patients with diabetes ( 62.4 + /- 10.2 years , 80 men ) were enrolled in the study . Sixty-nine ( 56.5 % ) were r and omly assigned to receive abciximab ( 34 with and 35 without preprocedural hyperglycemia ) and 53 ( 43.5 % ) to placebo ( 23 with and 30 without hyperglycemia ) . Target vessel revascularization was significantly lower in diabetic patients who received abciximab at 30 days ( 2.9 % and 2.8 % vs 8.7 % and 6.6 % in nonabciximab group with or without hyperglycemia , respectively , P < .01 ) but not at 6 months ( 31.4 % and 26.5 % vs 30 % and 28.7 % , P = NS ) . Conversely , the cumulative incidence of MACE was significantly higher among diabetic patients with preprocedural hyperglycemia ( 64.7 % and 65.2 % ) versus diabetic patients with preprocedural glycemic control ( 37.1 % and 40 % ) , treated with or without abciximab , respectively ( P < .05 ) . CONCLUSIONS A preprocedural hyperglycemia is associated with a higher rate of MACE , regardless of the use of abciximab , in diabetic patients undergoing elective coronary stenting
None of the trials examined the effects of the interventions in terms of costs .
AUTHORS ' CONCLUSIONS The included trials did not demonstrate significant differences for most of the outcomes when targeting intensive perioperative glycaemic control compared with conventional glycaemic control in patients with diabetes mellitus .
However , posthoc analysis indicated that intensive glycaemic control was associated with an increased number of patients experiencing hypoglycaemic episodes .
BACKGROUND Patients with diabetes mellitus are at increased risk of postoperative complications .
Data from r and omised clinical trials and meta-analyses point to a potential benefit of intensive glycaemic control , targeting near-normal blood glucose , in patients with hyperglycaemia ( with and without diabetes mellitus ) being su bmi tted to surgical procedures .
However , there is limited evidence concerning this question in patients with diabetes mellitus undergoing surgery .
OBJECTIVES To assess the effects of perioperative glycaemic control for diabetic patients undergoing surgery .